Dalfampridine
How it works: Treating relapses and symptoms →
Fampyra
EU: Approved in the EU since 2011US: FDA approved 2010
- Other names
- fampridine
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- Voltage-gated potassium channel blocker
- Targets
- Voltage-gated potassium channel
- Availability
- Authorised in all EU and EEA countries. Reimbursement is decided by each country.
Approvals
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
73,793 reports in total, 21,630 marked serious.
- Gait disturbance11,167
- Drug ineffective8,477
- Fall7,597
- Fatigue5,663
- Balance disorder4,997
- Multiple sclerosis relapse4,885
- Therapy cessation4,618
- Dizziness4,127
- Urinary tract infection3,878
- Asthenia3,590
Trials
Key trials
Large trials with a reported result on their main goal.
- RESTORE
Terminated · Phase 3 · MS (type not specified) · Stopped: no effect
- ENHANCE
Completed · Phase 3 · Relapsing and progressive · Main goal met
- Dalfampridine, phase 2 / phase 3
Completed · Phase 2 / Phase 3 · MS (type not specified) · Main goal not met
- Dalfampridine, phase 3
Completed · Phase 3 · MS (type not specified) · Main goal not met
- Dalfampridine, phase 3
Completed · Phase 3 · MS (type not specified) · Main goal met
- Dalfampridine, phase 3
Completed · Phase 3 · MS (type not specified) · Main goal met
Running now
- AmpPT
Recruiting · Phase 3 · MS (type not specified) · ongoing
- Dalfampridine, phase 4
Ongoing · Phase 4 · MS (type not specified) · ongoing
- Dalfampridine, phase 2
Ongoing · Phase 2 · MS (type not specified) · ongoing
Other trials (34)
Completed small trials, dose-finding studies and trials in other diseases.
- FAMP-ON
Status unknown · Early phase 1 · Optic neuritis · no_result_found
- MUST
Completed · Not a drug-phase study · MS (type not specified) · result_in_paper_unread
- FAMILY
Completed · MS (type not specified) · result_in_paper_unread
- Dalfampridine, phase 4
Completed · Phase 4 · MS (type not specified) · no_result_found
- Dalfampridine
Terminated · MS (type not specified) · stopped_other
- Dalfampridine, phase 2
Completed · Phase 2 · MS (type not specified) · Main goal not met
- Dalfampridine, phase 2
Completed · Phase 2 · MS (type not specified) · Main goal met
- Dalfampridine, phase 4
Status unknown · Phase 4 · MS (type not specified) · result_in_paper_unread
- RETRAP
Completed · Phase 4 · Relapsing and progressive · no_result_found
- Dalfampridine, phase 4
Completed · Phase 4 · Progressive MS · results_posted_no_test
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error